



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
---------------	-------------	----------------------	---------------------

08/430,035 04/27/95 EATON

18N2/0401

DARYL B WINTER
GENENTECH INC
460 POINT SAN BRUNO BOULEVARD
SOUTH SAN FRANCISCO CA 94080-4990

EXAMINER
SPECTOR, L

ART UNIT	PAPER NUMBER
----------	--------------

1812

DATE MAILED:

04/01/96

This is a communication from the examiner in charge of your application.
COMMISSIONER OF PATENTS AND TRADEMARKS

for restriction only
☒ This application has been examined ☐ Responsive to communication filed on ☐ This action is made final.

A shortened statutory period for response to this action is set to expire 0 month(s) 30 days from the date of this letter.
Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C. 133

Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION:

- | | |
|---|---|
| 1. <input type="checkbox"/> Notice of References Cited by Examiner, PTO-892. | 2. <input type="checkbox"/> Notice of Draftsman's Patent Drawing Review, PTO-948. |
| 3. <input type="checkbox"/> Notice of Art Cited by Applicant, PTO-1449. | 4. <input type="checkbox"/> Notice of Informal Patent Application, PTO-152. |
| 5. <input type="checkbox"/> Information on How to Effect Drawing Changes, PTO-1474. | 6. <input type="checkbox"/> |

Part II SUMMARY OF ACTION

1. ☒ Claims 1-27 are pending in the application.
Of the above, claims _____ are withdrawn from consideration.
2. ☐ Claims _____ have been cancelled.
3. ☐ Claims _____ are allowed.
4. ☐ Claims _____ are rejected.
5. ☐ Claims _____ are objected to.
6. ☒ Claims 1-27 are subject to restriction or election requirement.
7. ☐ This application has been filed with Informal drawings under 37 C.F.R. 1.85 which are acceptable for examination purposes.
8. ☐ Formal drawings are required in response to this Office action.
9. ☐ The corrected or substitute drawings have been received on _____. Under 37 C.F.R. 1.84 these drawings are ☐ acceptable; ☐ not acceptable (see explanation or Notice of Draftsman's Patent Drawing Review, PTO-948).
10. ☐ The proposed additional or substitute sheet(s) of drawings, filed on _____, has (have) been ☐ approved by the examiner; ☐ disapproved by the examiner (see explanation).
11. ☐ The proposed drawing correction, filed _____, has been ☐ approved; ☐ disapproved (see explanation).
12. ☐ Acknowledgement is made of the claim for priority under 35 U.S.C. 119. The certified copy has ☐ been received ☐ not been received ☐ been filed in parent application, serial no. _____; filed on _____.
13. ☐ Since this application appears to be in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.
14. ☐ Other _____

430035.R
3/29/96

EXAMINER'S ACTION

Part III: Detailed Office Action

Restriction Requirement:

Restriction to one of the following inventions is required under 35 U.S.C. § 121:

I. Claims 1-7, 24, 26 and 27, drawn to *mpl* ligand protein and compositions comprising *mpl* ligand and a cytokine, CSF or interleukin, classified in Class 530, subclass 351 and Class 424, subclass 85.1.

II. Claims 9 and 10, drawn to antibodies and hybridoma cells, classified in Class 530, subclass 387.1 and Class 435, subclass 240.27.

III. Claims 8 and 11-21, drawn to nucleic acids, expression vectors, host cells, method of expression and *mpl* ligand fusion proteins, classified in Class 536, subclass 23.5 and Class 435, subclasses 240.1, 320.1, 69.7 and 71.1.

IV. Claims 22 and 23, drawn to a nucleic acid hybridization assay and amplification method, classified in Class 453, subclasses 6 and 91.1.

V. Claim 25, drawn to a method of treatment using *mpl* ligand, classified in Class 514, subclass 12.

The inventions are distinct, each from the other because of the following reasons:

The nucleic acids of Invention III are related to the protein of Invention I by virtue of encoding same. The DNA molecule has utility for the recombinant production of the protein. Although the DNA molecule and protein are related since the DNA encodes the specifically claimed protein, they are distinct inventions because they are physically and functionally distinct chemical entities, and the protein product can be made by another and materially different process, such as by synthetic peptide synthesis or purification from the natural source. Further, the DNA may be used for processes other than the production of the protein, such as nucleic acid hybridization assay.

The proteins of Invention I are related to the antibodies of Invention II by virtue of being the cognate antigen, necessary for the production of the antibodies. Although the protein and antibody are related due to the necessary steric complementarity of the two, they are distinct inventions because they are physically and functionally distinct chemical entities, and because

the protein can be used another and materially different process from the use for production of the antibody, such as in a pharmaceutical composition in its own right, or to assay or purify the cognate receptor of the protein (as the protein is itself a ligand), or in assays for the identification of agonists or antagonists of the receptor protein.

5 The proteins and compositions of Invention I are distinct and unrelated to the methods of Invention IV, wherein each is not required for the other, and the proteins cannot be either used nor produced by the methods.

 Inventions I and V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using
10 the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)). In the instant case the product may be used as an antigen for the production of the antibodies of Invention II.

 The compositions of Inventions II and III are physically and functionally distinct products
15 which are capable of separate manufacture and use, and which have distinct biological and chemical properties.

 The cells of Inventions II and III are separate and distinct, as they have different biological and physical characteristics, and require divergent searches.

 The antibodies and cells of Invention II are patentably distinct from the methods of each
20 of Inventions IV and V, wherein the antibodies and cells may be neither produced by nor used in either of the methods.

 The nucleic acids of Invention III and methods of Invention IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another
25 materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)). In the instant case the product may be used for the recombinant production of the protein of Invention I.

 The products of Invention III and methods of Invention V are patentably distinct, wherein

the products may be neither made by nor used in the methods.

The methods of Inventions IV and V are independent and distinct processes of using different products, and involve separate process steps and results.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

Advisory Information:


Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Lorraine M. Spector, whose telephone number is (703) 308-1793. Dr. Spector can normally be reached Monday through Friday, 8:00 A.M. to 4:30 P.M.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Ms. Garnette D. Draper, can be reached at (703)308-4232.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist at telephone number (703) 308-0196.

Serial Number 08/430035
Art Unit 1812

Certain papers related to this application may be submitted to Group 1800 by facsimile transmission. Papers should be faxed to Group 1800 via the PTO Fax Center located in Crystal Mall 1 (CM1). The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). The Art Unit 1812 Fax Center number is (703) 308-0294. NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office. **Please** advise the Examiner at the telephone number above when a fax is being transmitted.


Lorraine Spector, Ph.D.
Patent Examiner

LMS
430035.R
3/29/96